A highly qualified and experienced biotech professional, with a strong background in molecular biology, genetics, and rare disease research and clinical practice. A proven track record of developing and leading successful projects and programs in collaboration with multi-stakeholders, including researchers, clinicians, industry partners, government, and patient groups. A passionate and effective advocate for the rare disease community, with a personal connection to Duchenne muscular dystrophy.
The Duchenne CAB is an independent, autonomous and international board of trained patient representatives (parents) from 12 different countries across the world
The Duchenne CAB provides its collective knowledge and expertise in a common endeavor to accelerate research, development, clinical trials and access to effective treatments for Duchenne worldwide
Developed and implemented the strategic initiatives for the organizations research funding, education, communications, and advocacy programs, which aims to find a cure for Duchennemuscular dystrophy and support families in need
Shaped solutions and approaches to advance the scientific and clinical development of novel therapies and patient support programs, to improve the standard of care and quality of life for individuals living with Duchenne
Developed and launched a clinical trial tool to help Duchenne families access information about clinical trials in Canada and across the globe.
Advanced the organization's directive to build and maintain strong relationships with researchers, clinicians, policy makers, industry partners, and patient groups.
Represented the organization and the Duchennecommunity at national and international conferences, meetings, and media events
Secures and manages funding and grants from various sources, such as government agencies, foundations, and corporate sponsors, to support the organization’s mission and vision.
Launched a Patient organization dedicated to spotlighting the Canadian Duchenne communities’ diverse needs, perspectives, and experiences into conversations with government, industry and the medical community to improve patient care, drug development, and access to new therapies
Developed and launched a Duchenne Canadian community platform where families and individuals with Duchenne Muscular Dystrophy can express their diverse needs and obtain support
Developed and lead the medical affairs strategy and activities for the neurology and rare disease portfolio, including multiple sclerosis and spinal muscular atrophy
Provided scientific and clinical expertise and support to internal and external stakeholders, such as medical science liaisons, sales and marketing teams, regulatory teams, health care professionals, and patient organizations
Developed and delivered scientific presentations, publications, and educational materials on the disease areas and products
Led and supported various medical projects, such as advisory boards, investigator-initiated trials, real-world evidence studies, and patient support programs. including the largest special access program for nusinersen
Thesis: Characterization of the human proglucagon enhancer regions responsible for expression of proglucagon in the A-cells of the pancreatic islets and intestinal L-cells
Designed and performed experiments included molecular cloning, PCR, DNA sequencing, electronic gel mobility shift assay, mammalian tissue culture, and transfection assays
Analyzed and interpreted data using various statistical and bioinformatics tools
Prepared and published research papers, posters, and abstracts in peer-reviewed journals and conferences
Compliance to Duchenne Muscular Dystrophy Care Considerations in Canada Osman, H, Lintern, S, Larocca, V, Adamji, Z, Beattie, E, Worsfold, N, Selby, K, Campbell, C, Lochmuller, H, The Canadian DMD Care Considerations Group Poster Session 86, 2023 Ottawa International Conference on Neuromuscular Disease & Biology
Mapping a national Duchenne Muscular Dystrophy registry to the International Classification of Functioning, Disability, and Health. Westbury, G, Bourcier, D, Hodgkinson, V, Dyck, A, Worsfold, N, Osman, H, Korngut, L, & Sheriko, J, on behalf of the CNDR Investigator Network Poster Session 34, 2023 Ottawa International Conference on Neuromuscular Disease & Biology
The Neuromuscular Disease Network for Canada (NMD4C): An interdisciplinary national collaboration to tackle unmet needs for NMD research and care Beattie, E, Amin, R, Brais B, Campbell, C, Warman-Chardon, J, Davis, J, Dowling, J, Gagnon, C, Gonorazky, H, Karamchandani, J, Korngut, L, Kothary, R, Lintern, S, McMillan, H, Oskoui, M, Osman, H, Selby, K, Worsfold, N, & Lochmüller, H, Poster Session 108, 2023 Ottawa International Conference on Neuromuscular Disease & Biology
A Collaborative National Duchenne Muscular Dystrophy (DMD) Registry for Real World Evidence. Hodgkinson-Brechenmacher, V.; McCormick, A.; Sheriko, J.; Lounsberry, J.; Osman, H.; Worsfold, N.; Campbell, C.; Mah, J.K.; McAdam, L.; Selby, K.;Koenig,N; Korngut, L.; CNDR Investigator Network, Poster Session EP.121, 2021 WMS
Uniting the Canadian NMD Community: One Year of the Neuromuscular Disease Network for Canada (NMD4C). Erin Beattie, James Dowling, Jodi Warman Chardon, Rashmi Kothary, Stacey Lintern, Reshma Amin, Teresa Buffone, Bernard Brais, Craig Campbell, Cynthia Gagnon, Hernan Gonorazky, Jason Karamchandani, Lawrence Korngut, Hugh McMillian, Maryam Oskoui, Homira Osman, Kathryn Selby, Daria Wojtal, Nicola Worsfold, and Hanns Lochmuller, Poster Session EP342, 2021 WMS
NMD4C: A New Neuromuscular Disease Network for Canada Kimberly Amburgey1, James Dowling1, Jodi Warman Chardon2, Rashmi Kothary3, Barbara Stead-Coyle4, Stacey Lintern4, Bernard Brais5, Craig Campbell6, Cynthia Gagnon7, Hugh McMillan8, Kathryn Selby9, Lawrence Korngut10, Maryam Oskoui11, Reshma Amin12, Perry Esler13, Nicola Worsfold13, Teresa Buffone14, Daria Wojtal4, Homira Osman4, and Hanns Lochmuller , Poster Session EP.348, 2020 WMS
· Duchenne Community Advisory Board (CAB) 2019-current
· Canadian Neuromuscular Disease Registry (CNDR) Investigator Network 2019-current
· Neuromuscular Disease Network 4 Canada (NMD4C) Knowledge user 2020-current
· Neuromuscular Disease Network 4 Canada (NMD4C) Investigator 2020-2022
· Patient partner leadership training, Canadian Organization for Rare Disorders (CORD) 2020-2021
· The Ontario Rare Disease Implementation Plan steering committee 2017-2018
· Project Hercules an international patient led multi stakeholder collaboration developing tools and evidence supporting HTA (Health Technology Assessment) for new treatments for Duchenne 2017-2021
· Hockey trainer for U15 girls Leaside Wildcats
· Member of the Hanlan Rowing Club master’s crew. Current volunteer coach, previous gold medalist at the 2017, 2016 and 2015 Ontario Masters Championships, gold medalist at the 2015 and 2018 Cora Welland Regatta, and 4th place finish at the Royal Canadian Henley regatta 2017.
· Enjoy all water sports (canoeing, kayaking), camping, biking, gourmet cooking, walking my dogs.
· Recipient of the Fredrick P. Ide Graduate Award
· Awarded a University of Toronto fellowship